Search

OBJECTIVE: To probe into the mechanism of Shenfu injection in the treatment of hemorrhagic shock based on network pharmacology and molecular docking technology. METHODS: The main components and action targets of Shenfu injection were obtained by Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform. Hemorrhagic shock related targets were obtained by searching the databases of GeneCards, Online Mendelian Inheritance in Man, therapeutic target database and Drugbank. The drug targets and disease targets were intersected and Venn diagram was drawn. The intersection targets were uploaded to STRING for visualization to obtain the proteinprotein interaction ( PPI) network diagram. Cytoscape 3. 9. 1 was used to construct the “ drug-component-targetdisease” network diagram. Gene ontology (GO) functional enrichment analysis and Kyoto encyclopedia of genes and genomes (KEGG) pathway enrichment analysis were performed by using R 4. 2. 1. Pymol 2. 4. 0 and AutoDock Tools 1. 5. 7 were used for molecular docking. RESULTS: The two components of Shenfu injection were ginseng and aconite extract, 25 active components were screened, and 30 common targets were obtained after intersected with drug targets and disease targets. The PPI diagram showed that the degree of TNF, CASP3, IL-1β, PTGS2, ESR1 and CASP8 were higher. The network diagram of Shenfu injection-active component-gene target-disease showed that Beta-sitosterol, Ginsenoside rh2, Deltoin, Karanjin and PTGS2, NCOA2, PTGS1, ADRB2 were of high biological importance. GO functional enrichment analysis mainly focused on the regulation of apoptosis and inflammatory factors. KEGG pathway enrichment analysis showed that influenza A and other pathways were associated with hemorrhagic shock. In molecular docking, the change of intermolecular binding energy of molecular docking confirmed that the effective components of Shenfu injection could bind stably to the target related to hemorrhagic shock. CONCLUSIONS: Shenfu injection has the characteristics of multi-components and multi-targets in the treatment of hemorrhagic shock, which may be related to its reduction of cell apoptosis and inhibition of inflammation. [ABSTRACT FROM AUTHOR]

OBJECTIVE: To probe into the effects of linazolamine combined with Shenfu injection intervention on serum tumor necrosis factor α (TNF-α), procalcitonin (PCT), hypersensitivity C-reactive protein (hs-CRP) levels and and acute physiological and chronic health evaluation Ⅱ (APACHE Ⅱ) score in patients with sepsis. METHODS: Totally 197 patients with sepsis admitted into Affiliated Fifth People’s Hospital of Chengdu University of Traditional Chinese Medicine Hospital from Jan. 2019 in Jan. 2021 were selected for retrospectively analysis, which were divided into control group and observation group according to the admission time. The 98 patients in the control group were treated with linazolamine injection, while the 99 patients in the observation group was given linazolamine combined with Shenfu injection. Changes of TNF-α, PCT, hs-CRP levels and APACHE Ⅱ score before and after treatment were compared between two groups. RESULTS: The serum TNF-α, PCT, hs-CRP levels and APACHE Ⅱ score in the observation group were significantly lower than those of the control group,with statistically significant differences (P<0. 05). All the TNF-α, PCT, hs-CRP levels and APACHE Ⅱ score were independent risk factors affecting the prognosis of patients with sepsis (P<0. 05), the APACHE Ⅱ score was positively associated with TNF-α, PCT and hs-CRP expression (P <0. 05). CONCLUSIONS: All the TNF-α, PCT, hs-CRP expression and APACHE Ⅱ score were independent risk factors of patients with sepsis, and the treatment of linazolamine combined with Shenfu injection can improve the clinical efficacy. [ABSTRACT FROM AUTHOR]

OBJECTIVE: Based on the rapid health technology assessment(HTA),to evaluate the efficacy,safety and economical efficiency of Shenfu injection in the treatment of cardiac failure, so as to provide evidence-based evidence for clinical rational drug application. METHODS: HTA reports, systematic reviews/ Meta-analyses and pharmacoeconomic studies on Shenfu injection in the treatment of cardiac failure were involved by overall retrieving CNKI,Wanfang database,CBM,EMBase,PubMed and the Cochrane Library,qualitative description was adopted to conduct analysis and summary on the involved studies,and quality evaluation on the literature and its methodology were performed. RESULTS: Totally 14 studies were involved,13 of which were systematic reviews/ Meta-analyses,1 was pharmacoeconomic study,no HTA report was retrieved. The analysis result indicated that the combination of Shenfu injection and western conventional therapy in the treatment of cardiac failure had obvious advantages in promoting clinical effective rate, improving TCM syndrome score, reducing brain natriuretic peptide level, improving left ventricular ejection fraction, increasing cardiac output, improving heart pump function, reduce N-terminal B-type pronatriuretic peptide level, promoting 6-min walking distance, improving left ventricular shortening fraction and reducing readmission rate of patients with cardiac failure; however, the research conclusions on reducing the left ventricular end diastolic diameter and mortality were inconsistent; meanwhile, no obvious adverse drug reactions [ABSTRACT FROM AUTHOR]

OBJECTIVE: To investigate and analyze the clinical application of shenfu injection in Shanghai Qingpu District Zhujiajiao People's Hospital (hereinafter referred to as "our hospital"), so as to promote the rational drug use in clinic. METHODS: 286 inpatient medical orders with application of shenfu injection from Jan. to Dec. 2013 were extracted, combined with drug instruction and Basic Principles of Traditional Chinese Medicine Injection in Clinical Use, patients' general information, usage and dosage, clinical diagnosis, solvent, route of administration, drips, treatment course, adverse reactions and medication expenses, etc, were statistically analyzed. RESULTS: Shenfu injection was widely used in many departments of our hospital, including department of surgery, orthopaedics and internal medicine, etc; and in many diseases including appendectomy, gallbladder disease surgery, acute pancreatitis, oblique hernia surgery, traumatic fracture surgery, anorectal disease and cardiovascular disease, etc. The number of patients with shenfu injection for 1~3 d took the lead, were respectively 48,61 and 45 cases. The compatibility of medicines was 13.81%, combination of two kinds of traditional Chinese medicine injection was 7.46%. There were 1 patient with improper usage, 3 patients with clear indication of slow drip and 2 patients of drug allergy history with traditional Chinese medicine injection. CONCLUSIONS: There are some problems and deficiencies in the selection of target diseases, expansion of disease, application methods, treatment course and observation on adverse reactions of shenfu injection. With the rational application of drug evaluation, clinical science strengthened by evidence-based medicine, the traditional Chinese medicine injection can better serve the public health. [ABSTRACT FROM AUTHOR]

OBJECTIVE: To probe into the efficacy of Shenfu injection in treatment of heart failure and its effect on high-sensitivity C-reactive protein ( hs-CRP ). METHODS: 94 patients with heart failure admitted into the First People's Hospital of Kashi from Jan.2016 to Jan.2017 were selected and divided into observation group and control group via the random number table, with 47 cases in each. Both groups were given conventional therapy, on that basis, the observation group was treated with Shenfu injection. Clinical efficacy, indices of cardiac function and levels of serum hs-CRP of two groups were observed. RESULTS: The total effective rate of observation group ( 89.36%, 42/47 ) was significantly higher than that of the control group ( 70.21%, 33/47 ), with statistically significantly difference (P<0.05);after treatment, the left ventricular ejection fraction (LVEF) of both groups were significantly higher than that of before treatment, and that of observation group was significantly higher the control group; the left ventricular end-diastolic diameters (LVEDD) and left ventricular end-systolic diameters (LVESD) of both groups were significantly lower than those of before treatment, and those of observation group was significantly lower than the control group, with statistically significantly differences (P<0.05); level of hs-CRP of observation group was significantly lower than that of before treatment and the control group, with statistically significantly differences ( P <0.05 ). CONCLUSIONS: The efficacy of Shenfu injection in treatment of heart failure is remarkable, which can significantly patients' cardiac function and relieve inflammatory reactions. [ABSTRACT FROM AUTHOR]

OBJECTIVE: To probe into the clinical efficacy of Shenfu injection combined with edaravone injection in treatment of acute cerebral infarction. METHODS: 120 patients with acute cerebral infarction admitted into Hengyang Traditional Chinese Medicine Hospital from Jun.2014 to Jun.2016 were selected and divided into control group and observation group via random number table, with 60 cases in each group. The control group was treated with edaravone injection, while the observation group was given Shenfu injection combined with edaravone injection, both groups received a 14-day treatment. The activities of daily living(ADL), national institutes of health stroke scale(NIHSS) scores and levels of inflammatory factors between two groups before and after treatment were compared, the clinical efficacy and incidence of adverse drug reactions of two groups were observed. RESULTS: Before treatment, there was no statistical significance in levels of ADL scores, NIHSS scores, C-reactive protein(CRP), tumor necrosis factor α(TNF-α) and interleukin 6(IL-6) between two groups(P>0.05). After treatment, the ADL scores of both groups had been significantly increased, and that of the observation group was significantly higher than the control group;the NIHSS scores, CRP, TNF-α and IL-6 of both groups had been significantly decreased, and those of the observation group were significantly lower than the control group, with statistically significant differences (P<0.05). The total effective rate of observation group was 93.33%(56/60), which was significantly higher than that of the control group (80.00%, 48/60), with statistically significant difference(P<0.05). The incidence of adverse drug reactions of observation group was 6.67%(4/60), that of the control group was 3.33%(2/60), the difference had no statistical significance (P>0.05). CONCLUSIONS: The efficacy of Shenfu injection combined with edaravone injection in treatment of acute cerebral infarction is remarkable, with high safety. [ABSTRACT FROM AUTHOR]